Edition:
United States

Johnson & Johnson (JNJ.N)

JNJ.N on New York Stock Exchange

132.48USD
4:00pm EDT
Change (% chg)

$2.05 (+1.57%)
Prev Close
$130.43
Open
$131.02
Day's High
$132.88
Day's Low
$130.58
Volume
2,100,457
Avg. Vol
1,912,853
52-wk High
$148.32
52-wk Low
$118.62

Latest Key Developments (Source: Significant Developments)

Janssen Submits U.S. & EU Regulatory Applications Seeking Approval Of Darzalex
Wednesday, 8 Aug 2018 07:30am EDT 

Aug 8 (Reuters) - Johnson & Johnson ::JANSSEN SUBMITS U.S. & EU REGULATORY APPLICATIONS SEEKING APPROVAL OF DARZALEX® (DARATUMUMAB) SPLIT DOSING REGIMEN.JANSSEN SAYS APPLICATIONS SEEK TO UPDATE CERTAIN PRODUCT CHARACTERISTICS TO GIVE PROFESSIONALS OPTION TO SPLIT FIRST INFUSION OF DARZALEX OVER 2 DAYS.  Full Article

Janssen's Tremfya Receives First Two Positive Assessments In Europe
Wednesday, 13 Jun 2018 09:07am EDT 

June 13 (Reuters) - Johnson & Johnson ::JANSSEN’S TREMFYA®▼ (GUSELKUMAB) RECEIVES ITS FIRST TWO POSITIVE HEALTH TECHNOLOGY ASSESSMENTS IN EUROPE.JANSSEN PHARMACEUTICAL - UK'S NICE PUBLISHED POSITIVE GUIDANCE FOR TREMFYA, FOLLOWING POSITIVE FINAL APPRAISAL DETERMINATION DELIVERED ON 2 MAY.  Full Article

Fujirebio Says Entered Into Agreement With Janssen Pharmaceuticals
Thursday, 26 Apr 2018 07:30am EDT 

April 26 (Reuters) - Miraca Holdings Inc <4544.T>::FUJIREBIO SAYS ENTERED INTO AGREEMENT WITH JANSSEN PHARMACEUTICALS TO DEVELOP & COMMERCIALIZE AMYLOID Β 42/40 RATIO ASSAY.FUJIREBIO - ASSAY INTENDED TO IDENTIFY PATIENTS WHO MAY BENEFIT FROM TREATMENT WITH JANSSEN'S NEW INVESTIGATIONAL ORAL BACE INHIBITOR, ATABECESTAT.  Full Article

U.S. FDA Says Cleared Contact Lens To Incorporate Additive That Automatically Darkens Lens When Exposed To Bright Light
Tuesday, 10 Apr 2018 01:32pm EDT 

April 10 (Reuters) - U.S. Food & Drug Administration::U.S. FOOD & DRUG ADMINISTRATION SAYS CLEARED FIRST CONTACT LENS TO INCORPORATE ADDITIVE THAT AUTOMATICALLY DARKENS LENS WHEN EXPOSED TO BRIGHT LIGHT.U.S. FDA SAYS GRANTED CLEARANCE OF THE ACUVUE OASYS CONTACT LENSES WITH TRANSITIONS LIGHT INTELLIGENT TECHNOLOGY TO JOHNSON & JOHNSON VISION CARE INC.  Full Article

Dominic Caruso To Retire As Chief Financial Officer Of Johnson & Johnson
Tuesday, 20 Mar 2018 04:15pm EDT 

March 20 (Reuters) - Johnson & Johnson ::DOMINIC J. CARUSO TO RETIRE AS CHIEF FINANCIAL OFFICER OF JOHNSON & JOHNSON.J&J - ‍DOMINIC J. CARUSO TO RETIRE AS CHIEF FINANCIAL OFFICER​.J&J - ‍JOSEPH WOLK PROMOTED TO EXECUTIVE VICE PRESIDENT, CHIEF FINANCIAL OFFICER​.  Full Article

Janssen Announces FDA Breakthrough Therapy Designation For Erdafitinib In The Treatment Of Metastatic Urothelial Cancer
Thursday, 15 Mar 2018 08:00am EDT 

March 15 (Reuters) - Johnson & Johnson ::JANSSEN ANNOUNCES U.S. FDA BREAKTHROUGH THERAPY DESIGNATION FOR ERDAFITINIB IN THE TREATMENT OF METASTATIC UROTHELIAL CANCER.JANSSEN PHARMACEUTICAL - BREAKTHROUGH THERAPY DESIGNATION BASED ON DATA FROM MULTICENTER, OPEN-LABEL PHASE 2 CLINICAL TRIAL OF ERDAFITINIB.  Full Article

J&J Says CEO Alex Gorsky's FY 2017 Total Compensation Was $29.8 Mln Vs $26.9 Mln In FY 2016
Wednesday, 14 Mar 2018 08:25am EDT 

March 14 (Reuters) - Johnson & Johnson ::J&J SAYS CHAIRMAN AND CEO ALEX GORSKY'S FY 2017 TOTAL COMPENSATION WAS $29.8 MILLION VERSUS $26.9 MILLION IN FY 2016 - SEC FILING.J&J - CFO DOMINIC CARUSO'S TOTAL COMPENSATION FOR 2017 WAS $11.7 MILLION VERSUS $11.3 MILLION IN 2016.J&J - EVP, WORLDWIDE CHAIRMAN PHARMACEUTICALS JOAQUIN DUATO'S TOTAL COMPENSATION FOR 2017 WAS $19.4 MILLION VERSUS $10.1 MILLION IN 2016.  Full Article

Aldeyra Therapeutics Announces Agreement With Johnson & Johnson Innovation To Advance Novel Immune-Modulating Drugs
Tuesday, 27 Feb 2018 08:00am EST 

Feb 27 (Reuters) - Aldeyra Therapeutics Inc ::ALDEYRA THERAPEUTICS ANNOUNCES AGREEMENT WITH JOHNSON & JOHNSON INNOVATION TO ADVANCE NOVEL IMMUNE-MODULATING DRUGS FOR SYSTEMIC INFLAMMATORY DISEASES.ALDEYRA THERAPEUTICS INC - ‍ ENTERED INTO A COLLABORATIVE RESEARCH AGREEMENT WITH JANSSEN RESEARCH & DEVELOPMENT​.ALDEYRA - ‍ AGREEMENT WITH JANSSEN TO ADVANCE DEVELOPMENT OF EXISTING ANALOGS OF REPROXALAP FOR TREATMENT OF SYSTEMIC INFLAMMATORY DISEASES​.ALDEYRA THERAPEUTICS INC - WILL COLLABORATE WITH JANSSEN ON RESEARCH ACTIVITIES, WHICH WILL BE GOVERNED BY A JOINT SCIENTIFIC REVIEW COMMITTEE​.ALDEYRA - ‍ FOR A LIMITED PERIOD, SUBJECT TO CONDITIONS, JANSSEN TO RETAIN OPTION TO NEGOTIATE EXCLUSIVE LICENSE PERTAINING TO COMPOUNDS DEVELOPED.  Full Article

FDA Approves Janssen Pharmaceutical's Erleada For A Certain Type Of Prostate Cancer
Wednesday, 14 Feb 2018 01:52pm EST 

Feb 14 (Reuters) - The U.S. Food and Drug Administration::SAYS APPROVED JANSSEN PHARMACEUTICAL'S ERLEADA FOR A CERTAIN TYPE OF PROSTATE CANCER USING NOVEL CLINICAL TRIAL ENDPOINT‍​.  Full Article

‍Janssen Submits Marketing Authorisation Application To EMA For Apalutamide
Friday, 9 Feb 2018 03:00am EST 

Feb 9 (Reuters) - :‍JANSSEN SUBMITS MARKETING AUTHORISATION APPLICATION FOR APALUTAMIDE TO TREAT PATIENTS WITH HIGH-RISK NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER​.‍JANSSEN PHARMACEUTICAL - SUBMITTED MARKETING AUTHORISATION APPLICATION TO EUROPEAN MEDICINES AGENCY (EMA) FOR APALUTAMIDE​.  Full Article

Photo

Trump administration proposes production quota cuts for six opioids

WASHINGTON/NEW YORK The Trump administration on Thursday proposed that U.S. drugmakers cut production quotas of the six most abused opioids by 10 percent next year to fight a nationwide addiction crisis. | Video